https://www.biopharmadive.com/news/travere-fda-approve-flispari-fsgs-kidney-disease/817415/
Travere wins long-awaited approval for kidney disease drug | BioPharma Dive
The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity believed to be worth more than $1...
long awaitedkidney diseasewinsapproval
https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-travere-therapeutics-inc---tvtx-302286684.html
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such...
shareholder alertlaw firm
https://web.cvent.com/event/db9b7fce-1816-47fb-978a-2470be2132ec/summary
Summary - Travere FSGS Cross-functional Launch Event. Online registration by Cvent
launch eventonline registrationsummaryfsgscross
https://www.fool.com/investing/2021/08/16/heres-why-travere-therapeutics-stock-is-climbing-t/
Here's Why Travere Therapeutics Stock Is Climbing Today | The Motley Fool
Aug 16, 2021 - Investors are cheering positive phase 3 trial results with sparsentan that suggest it could become an important new treatment for a rare kidney disease.
https://www.sofi.com/invest/stock/TVTX/
Buy Travere Therapeutics Stock - TVTX Stock Price, Quote & News | SoFi
See real time price charts for TVTX stock, historical data, and recent news. Buy TVTX stock online with no commission fees.
price quotebuytherapeuticsstocknews
https://markets.businessinsider.com/news/stocks/analysts-offer-insights-on-healthcare-companies-siemens-healthineers-ag-othersemhf-and-travere-therapeutics-tvtx-1035999703
Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF) and Travere...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Siemens Healthineers AG (SEMHF) and Travere T...
siemens healthineers aghealthcare companies
https://www.globenewswire.com/fr/news-release/2024/10/14/2962853/0/en/travere-therapeutics-to-present-abstracts-at-american-society-of-nephrology-asn-kidney-week-2024.html
Travere Therapeutics to Present Abstracts at American
Travere Therapeutics will present 11 abstracts, including one late-breaking abstract, at the upcoming ASN Kidney Week 2024 in San Diego....
therapeuticspresentabstractsamerican
https://www.entrepreneur.com/business-news/travere-therapeutics-still-on-the-rise-after-encouraging/390646
Travere Therapeutics Still On The Rise After Encouraging Data
Sep 3, 2025 - Travere Therapeutics (NASDAQ: TVTX) is up a whopping 75.81% in the past three months, as shares of the biotech company climb out of a steep correction.
on the risetherapeuticsstillencouragingdata
https://www.benzinga.com/analyst-ratings/23/08/33922491/the-latest-analyst-ratings-for-travere-therapeutics
The Latest Analyst Ratings for Travere Therapeutics - Travere Therapeutics (NASDAQ:TVTX) - Benzinga
the latestanalyst ratingstherapeuticsnasdaqbenzinga